{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-225486","form_type":"8-K","ticker":"ZVRA","cik":"0001434647","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2023-08-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.914720+00:00","generated_at":"2026-06-11T01:07:02.520248+00:00","sec_items":["1.01","2.03","3.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Zevra Therapeutics to acquire Acer Therapeutics in stock-and-CVR merger","bullets":["Acer stockholders receive 0.120 Zevra shares per share plus one CVR; Zevra to issue ~2.96M shares.","CVR milestones include up to $34M tied to OLPRUVA net sales, plus payments for FDA approvals of OLPRUVA and EDSIVO.","Zevra provides $10M initial bridge loan at 12% to Acer; total facility up to $16.5M.","Zevra purchases Acer debt from Nantahala: ~$20.2M SWK loans and ~$15.1M Marathon convertible notes.","Acer pays $3M termination fee if it accepts superior proposal or breaches non-solicitation."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-225486","json":"https://secwatch.observer/filing/0001193125-23-225486.json","markdown":"https://secwatch.observer/filing/0001193125-23-225486.md","text":"https://secwatch.observer/filing/0001193125-23-225486.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434647/000119312523225486/0001193125-23-225486-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434647/000119312523225486/d547103d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T01:07:02.520248+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"61f97e3d85eaa5e61ad738d98617103c5e26a043","claim":"ZEVRA THERAPEUTICS, INC. entered into Agreement and Plan of Merger with Acer Therapeutics Inc. (effective 2023-08-30).","evidence_excerpt":"On August 30, 2023, Zevra Therapeutics, Inc., a Delaware corporation (“ Zevra ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among Zevra, Aspen Z Merger Sub, Inc., a Delaware corporation and an indirect wholly-owned subsidiary of Zevra (“ Merger Sub ”), and Acer Therapeutics Inc., a Delaware corporation (“ Acer ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434647/000119312523225486/0001193125-23-225486-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Acer Therapeutics Inc."},{"label":"Effective","value":"2023-08-30"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}